When cancer cells are threatened, their mutation rate increases, resulting in the development of ways to evade the immune system and become resistant to anti-cancer therapies that were previously effective
By focusing on the development of efficacious and highly selective targeted therapeutics in oncology, AUM’s goal is to advance a portfolio of precision therapeutics designed to reverse cancer resistance
The rapid pace of scientific advancement heralded by the development of molecular biology has enabled a greater understanding of cancer at a molecular level. This has opened the door to the development of targeted therapies that address precise signalling pathways or molecular aberrations. However, drug development remains a highly complex process with a stringent regulatory framework resulting in an approval process that is complex and varies across countries and regions. On an average, it takes ten to twelve years for a new medicine to complete its journey from the laboratory to the market, with the clinical trial phase alone taking six to seven years.
Developing a pipeline of efficacious and highly selective targeted oncology therapeutics
AUM focuses on identifying and developing “niche busters“ targeting highly selective oncology therapeutics. To achieve this, validation of a drug molecules efficacy as shown by early scientific read-out of the biomarker impact is essential. Hence, AUM has a mandate of “No biomarker, No drug”. Such an approach will improve the probability of future success and increase the overall portfolio value for AUM.